This department is offering the Alzheimers Disease Drug Development Program (U01) to stimulate research in the pre-clinical development and testing of novel therapeutic compounds targeting Alzheimer’s disease. The goal is to slow, halt, or reverse cognitive decline and modify behavioral symptoms in AD, with a focus on IND application readiness. This grant excludes mechanistic/basic studies and clinical trials, emphasizing therapy development. The NIA has allocated $2.5M for FY2009, with funding varying based on research scope and quality. Applications tailored to begin human clinical testing of potential new therapies are encouraged. Closing date: May 07, 2011.
Opportunity ID: 43563
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-08-266 |
| Funding Opportunity Title: | Alzheimers Disease Drug Development Program (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Dec 03, 2008 |
| Last Updated Date: | Feb 25, 2011 |
| Original Closing Date for Applications: | Jan 07, 2012 |
| Current Closing Date for Applications: | May 07, 2011 |
| Archive Date: | Jun 07, 2011 |
| Estimated Total Program Funding: | $2,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education For profit organizations other than small businesses Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations). |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | -Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer’s disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. -Mechanism of Support. This FOA uses the NIH U01 mechanism -Funds Available and Anticipated Number of Awards. NIA has set aside $2.5 M in total costs in FY2009 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-08-266.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Modified to change Close Date to May 7, 2011 per NOT-OD-11-048 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-048.html). | Feb 25, 2011 | |
| Feb 25, 2011 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-08-266 |
| Funding Opportunity Title: | Alzheimers Disease Drug Development Program (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Dec 03, 2008 |
| Last Updated Date: | Feb 25, 2011 |
| Original Closing Date for Applications: | Jan 07, 2012 |
| Current Closing Date for Applications: | May 07, 2011 |
| Archive Date: | Jun 07, 2011 |
| Estimated Total Program Funding: | $2,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education For profit organizations other than small businesses Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations). |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | -Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer’s disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. -Mechanism of Support. This FOA uses the NIH U01 mechanism -Funds Available and Anticipated Number of Awards. NIA has set aside $2.5 M in total costs in FY2009 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-08-266.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-08-266 |
| Funding Opportunity Title: | Alzheimers Disease Drug Development Program (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 25, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 07, 2012 |
| Archive Date: | Feb 07, 2012 |
| Estimated Total Program Funding: | $2,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses Private institutions of higher education Public and State controlled institutions of higher education State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations). |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | -Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer’s disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. -Mechanism of Support. This FOA uses the NIH U01 mechanism -Funds Available and Anticipated Number of Awards. NIA has set aside $2.5 M in total costs in FY2009 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-08-266.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
There are no packages on this grant.
Leave a Reply